Activist Murchinson Slams Nano Dimension's $890M Acquisition Plan, Citing "Significant Dilution"
Summary
Activist investor Murchinson, a significant shareholder, is publicly opposing Nano Dimension's recently announced $890 million acquisition of Infinite Epigenetics. Murchinson views the deal as a misallocation of resources that would significantly dilute existing shareholders and intends to continue objecting to what it calls "entrenchment-driven value-destructive" initiatives. This strong opposition follows Nano Dimension's announcement earlier today of the non-binding term sheet for the Infinite Epigenetics acquisition, which represents a major strategic pivot. It also significantly escalates the ongoing proxy battle between Murchinson and Nano Dimension's board, which has been intensifying since Murchinson demanded a special shareholder meeting in May to replace directors. The proposed acquisition is massive, valued at nearly three times Nano Dimension's current market cap, and comes amidst the company's significant net losses and disclosed material weakness in financial reporting. Murchinson's vocal opposition, given its ~15% stake, could jeopardize the deal and further destabilize the company's leadership and strategic direction. The Extraordinary General Meeting on July 31, 2026, where shareholders will vote on Murchinson's proposals, will be critical as this new acquisition controversy adds significant leverage to the activist's position.
At the time of this announcement, NNDM was trading at $1.23 on NASDAQ in the Technology sector, with a market capitalization of approximately $309.9M. The 52-week trading range was $1.20 to $2.32. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.